Basel, Switzerland, 7 July 2025 – Lonza, one of the world's largest contract development and manufacturing organizations (CDMOs), today announced the launch of 4D-Nucleofector® LV Unit PRO, their next-generation large-scale electroporation unit designed to deliver clinically relevant cargos into large volumes of T cells. This unit builds on Lonza's well-established non-viral large-scale transfection platform and is optimized for CRISPR-based genome engineering and other advanced cell therapy applications.
For more than twenty years, Lonza's Nucleofector® Technology has been a cornerstone in cell and gene therapy R&D, enabling efficient delivery into hard-to-transfect primary cells, such as T cells. The newly introduced 4D-Nucleofector® LV Unit PRO further advances this technology, offering enhanced performance for CRISPR-based knock-out, knock-in and transposition.
A key innovation is the implementation of the new Nucleocuvette® Cartridges PRO, an improved cartridge version that enables the electroporation of complex cargos into up to one billion cells per run. The new cartridge supports complex clinically-relevant cargo delivery and introduces several usability improvements, including greater flexibility, simplified loading and clearing, and increased robustness of the flow-through process. The upgraded system is suited for preclinical studies and process development, serving as a scalable and reproducible platform for a seamless translation from discovery projects to GMP-compliant manufacturing for next-generation cell and gene therapies.
Mike Goetter, Head of Bioscience, Lonza, said: "Lonza's large-scale 4D-Nucleofector® LV Unit has been pivotal in supporting non-viral manufacturing of advanced therapy medicinal products. With the launch of the next-generation 4D-Nucleofector® LV Unit PRO, we are extending these capabilities to support GMP manufacturing across scales, enabling smoother process development and a seamless translation from R&D to clinical manufacture."
Additional Information
To learn more about Lonza’s Bioscience offerings, visit bioscience.lonza.com
To learn more about the 4D-Nucleofector® LV Unit PRO, visit: bioscience.lonza.com/large-scale-electroporation
Lonza Contact Details
media@lonza.com
Disclaimer
Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory.
Lonza Group Ltd. and its affiliates (collectively and individually, “Lonza”) make efforts to include accurate and up-to-date information. However, Lonza makes no representations or warranties, express or implied, including as to accuracy or completeness of information. All trademarks belong to Lonza, and are registered in the USA, EU and/or CH, or used in common law, or belong to third-party owners and are used for only informational purposes. All third-party copyrights have been reproduced with permission from their owners. The user bears the sole responsibility for determining the existence of any third-party rights and obtaining any necessary licenses and approvals. For more information, including regarding legal disclaimers, Lonza’s intellectual property rights, and how Lonza collects, uses and protects personal information: www.lonza.com/legal, www.lonza.com/about-us/strategy/intellectual-property and www.lonza.com/privacy.